Tremfya Market

Tremfya Market Analysis and Forecast by Fact.MR

• The global Tremfya market is estimated at US$ 4.1 billion in 2025 and has been forecast to expand at a CAGR of 7.8% to reach US$ 9.3 billion by 2036.
• Tremfya (guselkumab) is a selective interleukin-23 (IL-23) inhibitor biologic developed by Johnson and Johnson for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis
• Biologic monotherapy accounts for the largest product share, with plaque psoriasis representing the dominant indication.
• Subcutaneous injection is the primary administration route, delivered through prefilled syringes and auto-injector pens. Hospitals and specialty dermatology clinics form the primary prescribing and treatment settings.

Summary of Tremfya Market

• Market Snapshot
  • In 2025, the global Tremfya Market was valued at approximately USD 4.1 billion.
  • The market is estimated to reach USD 4.4 billion in 2026 and is projected to attain USD 9.3 billion by 2036.
  • The tremfya market is likely to expand at a CAGR of 7.8% during the forecast period.
  • The market is anticipated to create an absolute dollar opportunity of USD 4.9 billion between 2026 and 2036.
  • Biologic Monotherapy accounts for 42.6% of product share in 2026.
  • India (9.1%) and China (8.5%) are the key growth markets during the forecast period.
• Demand and Growth Drivers
  • Moderate-to-severe plaque psoriasis prevalence affecting over 125 million people globally creates a large addressable patient population for IL-23 inhibitor therapy.
  • Psoriatic arthritis indication expansion provides dual-indication prescribing rationale that broadens the eligible treatment population beyond dermatology into rheumatology.
  • Superior long-term efficacy data for IL-23 inhibitors versus TNF inhibitors in plaque psoriasis is shifting treatment algorithms toward IL-23 blockade as a preferred biologic class.
  • Auto-injector formulation availability enables patient self-administration at home, reducing clinic visit burden and improving treatment convenience and adherence.
  • Emerging market biologic access expansion through patient assistance programs and biosimilar competition in adjacent classes is broadening the overall biologic-eligible population.
• Product and Segment View
  • Biologic Monotherapy accounts for 42.6% of the product segment in 2026, supported by strong installed base and continued procurement across primary end use channels.
  • Plaque Psoriasis accounts for 48.1% of the indication segment in 2026, reflecting concentrated demand across established application areas.
  • Interleukin 23 Inhibition accounts for 55.3% of the mechanism of action segment in 2026, with adoption rising across both developed and emerging markets.
  • Key segmentation includes:
    • Product: Biologic Monotherapy, Combination Therapy, Auto Injector Formulation
    • Indication: Plaque Psoriasis, Psoriatic Arthritis, Inflammatory Skin Disorders
    • Mechanism of Action: Interleukin 23 Inhibition, Immune Modulation
    • Route of Administration: Subcutaneous Injection, Hospital Administration
  • These systems enable:
    • Targeted procurement and specification alignment across buyer segments
    • Performance benchmarking across product and application categories
    • Regional demand mapping across 30 plus countries
• Geography and Competitive Outlook
  • North America accounts for a large share of global demand, supported by established procurement channels and a mature buyer base.
  • Europe shows stable demand, with Germany (6.8%) contributing through regulatory compliance and institutional procurement for tremfya products.
  • Asia Pacific demand is led by India (9.1%) and China (8.5%).
  • India (9.1%) and China (8.5%) are the fastest growing country markets during the forecast period.
  • Leading companies include Johnson & Johnson Services Inc., AbbVie Inc., Novartis AG, Eli Lilly & Company, UCB S.A..
• Analyst Opinion
  • Shambhu Nath Jha, Principal Consultant at Fact.MR, says 'The Tremfya market reflects the broader structural shift in psoriasis treatment from TNF inhibitors toward targeted IL-23 blockade. Johnson and Johnson holds a strong position through first-mover advantage in the IL-23 class, but AbbVie risankizumab (Skyrizi) is competing aggressively for market share with head-to-head clinical data and broader indication coverage. Growth will be shaped by new indication approvals, particularly in inflammatory bowel disease, emerging market expansion, and the ability to maintain market share as the IL-23 class becomes increasingly competitive.'

Key Growth Drivers, Constraints, and Opportunities

Key Factors Driving Growth

• Moderate-to-severe plaque psoriasis prevalence affecting over 125 million people globally creates a large addressable patient population for IL-23 inhibitor therapy.
• Psoriatic arthritis indication expansion provides dual-indication prescribing rationale that broadens the eligible treatment population beyond dermatology into rheumatology.
• Superior long-term efficacy data for IL-23 inhibitors versus TNF inhibitors in plaque psoriasis is shifting treatment algorithms toward IL-23 blockade as a preferred biologic class.

Key Market Constraints

• High annual treatment cost, typically exceeding USD 50,000 per patient in the U.S., creates payer prior authorization barriers and restricts access in cost-sensitive healthcare systems.
• Competition from other IL-23 inhibitors (risankizumab, tildrakizumab) and IL-17 inhibitors (secukinumab, ixekizumab) fragments market share within the advanced psoriasis therapy class.
• Biosimilar entry risk for guselkumab as patent exclusivity approaches expiration creates long-term revenue uncertainty for the originator product.

Key Opportunity Areas

• New indication development in inflammatory bowel disease (Crohn disease, ulcerative colitis) could substantially expand the total addressable market for guselkumab beyond dermatology.
• Subcutaneous auto-injector convenience and extended dosing intervals (every 8 weeks maintenance) support treatment adherence advantages over more frequently dosed competitors.
• Emerging market launch expansion in India, Brazil, and Southeast Asia where biologic psoriasis treatment penetration remains low represents a large untapped patient population.

Segment-wise Analysis of the Tremfya Market

• Biologic Monotherapy holds 42.6% of the product segment in 2026, supported by established demand channels and continued procurement across primary end use applications.
• Plaque Psoriasis holds 48.1% of the indication segment in 2026, supported by established demand channels and continued procurement across primary end use applications.
• Interleukin 23 Inhibition holds 55.3% of the mechanism of action segment in 2026, supported by established demand channels and continued procurement across primary end use applications.

The tremfya market is segmented by product, indication, mechanism of action, route of administration, and region.

By product, the market covers Biologic Monotherapy, Combination Therapy, Auto Injector Formulation.

By indication, coverage includes Plaque Psoriasis, Psoriatic Arthritis, Inflammatory Skin Disorders.

Which Product Segment Dominates the Tremfya Market?

Biologic Monotherapy is expected to account for 42.6% of the product segment in 2026. Within this category, Interleukin 23 Inhibitor Monotherapy, Guselkumab Standard Dose represent the primary sub-segments generating procurement activity. The depth of the biologic monotherapy installed base across product applications sustains replacement demand and limits share erosion from newer alternatives in the tremfya market.

Combination Therapy is the second largest category in the product segment, with demand concentrated in Tremfya with Methotrexate and Tremfya with Topical Agents. Growth in combination therapy reflects shifting buyer requirements within the tremfya market toward this category.

Which Indication Segment Dominates the Tremfya Market?

Plaque Psoriasis is expected to account for 48.1% of the indication segment in 2026. Within this category, Moderate Plaque Psoriasis, Severe Plaque Psoriasis represent the primary sub-segments generating procurement activity. The depth of the plaque psoriasis installed base across indication applications sustains replacement demand and limits share erosion from newer alternatives in the tremfya market.

Psoriatic Arthritis is the second largest category in the indication segment, with demand concentrated in Peripheral Psoriatic Arthritis and Axial Psoriatic Arthritis. Growth in psoriatic arthritis reflects shifting buyer requirements within the tremfya market toward this category.

Which Mechanism of Action Segment Dominates the Tremfya Market?

Interleukin 23 Inhibition is expected to account for 55.3% of the mechanism of action segment in 2026. Within this category, p19 Subunit Targeting, Selective IL-23 Blockade represent the primary sub-segments generating procurement activity. The depth of the interleukin 23 inhibition installed base across mechanism of action applications sustains replacement demand and limits share erosion from newer alternatives in the tremfya market.

Immune Modulation is the second largest category in the mechanism of action segment, with demand concentrated in T Cell Pathway Regulation and Cytokine Reduction Mechanism. Growth in immune modulation reflects shifting buyer requirements within the tremfya market toward this category.

Which Product Trend is Shaping the Next Phase of Growth in the Tremfya Market?

Extended dosing intervals represent the key competitive advantage shaping Tremfya positioning within the IL-23 inhibitor class. Guselkumab maintenance dosing every 8 weeks compares favorably with some competing biologics that require more frequent administration, creating a patient convenience and adherence advantage. Clinical data showing sustained PASI 90 and PASI 100 responses over multiple years reinforces the durability of IL-23 inhibition as a treatment approach.

The competitive landscape within the IL-23 class is intensifying as risankizumab (AbbVie) and tildrakizumab (Sun Pharma) compete for the same patient population. Differentiation is increasingly driven by clinical trial data comparing head-to-head efficacy, dosing convenience, and real-world outcomes registry results. Johnson and Johnson is responding by investing in new indication development and auto-injector formulation improvements that maintain Tremfya competitiveness as the IL-23 inhibitor class matures.

Regional Outlook Across Key Markets

• India is growing at 9.1%, supported by expanding biologic access, patient assistance programs, and private insurance growth.
• China is growing at 8.5%, supported by NRDL biologic inclusion, urban dermatology expansion, and psoriasis awareness growth.
• USA is growing at 7.9%, supported by high biologic adoption, specialty pharmacy infrastructure, and dual-indication prescribing.
• Germany is growing at 6.8%, supported by G-BA benefit assessment, DDG guideline positioning, and statutory health insurance coverage.

CAGR Table

Source: Fact MR (FMR) analysis, based on proprietary forecasting model and primary research.

Market Outlook for Tremfya in India

The India Tremfya market is projected to grow at a CAGR of 9.1% through 2036. India is the fastest-growing Tremfya market, driven by expanding biologic access for psoriasis through patient assistance and private insurance coverage.

• Growing biologic prescribing for moderate-to-severe psoriasis among dermatologists in major cities is expanding the treatment-eligible population.
• Patient assistance programs by Johnson and Johnson India support affordability for patients unable to cover full treatment cost.
• Private health insurance expansion is gradually improving biologic therapy access for employed and insured populations.

Tremfya Demand Trends in China

The China Tremfya market is projected to grow at a CAGR of 8.5% through 2036. China is a high-growth Tremfya market supported by NRDL biologic inclusion and expanding dermatology specialty care.

• National Reimbursement Drug List (NRDL) negotiations for biologic psoriasis therapies are improving patient access and institutional prescribing.
• Urban tertiary hospital dermatology departments are primary prescribing centers for IL-23 inhibitors in China.
• Growing awareness of psoriasis as a treatable chronic condition is increasing patient willingness to seek advanced therapy.

USA Tremfya Market Growth Outlook

The USA Tremfya market is projected to grow at a CAGR of 7.9% through 2036. The U.S. is the largest single-country Tremfya market, driven by high biologic adoption rates and specialty pharmacy infrastructure.

• Commercial insurance and Medicare Part D coverage with prior authorization support access to IL-23 inhibitor therapy.
• Specialty pharmacy dispensing through CVS, OptumRx, and Express Scripts manages distribution and patient support services.
• Dermatology and rheumatology specialist prescribing drives treatment initiation for both psoriasis and psoriatic arthritis indications.

Germany Tremfya Market Demand Analysis

The Germany Tremfya market is projected to grow at a CAGR of 6.8% through 2036. Germany is a leading European Tremfya market, supported by G-BA benefit assessment and statutory health insurance coverage.

• G-BA AMNOG assessment of guselkumab has established its added benefit versus comparator therapies, supporting reimbursement.
• German Dermatological Society (DDG) treatment guidelines position IL-23 inhibitors as a preferred biologic class for moderate-to-severe psoriasis.
• Specialty dermatology clinics and university hospital departments are the primary prescribing and monitoring centers.

Tremfya Market Growth Assessment in Saudi Arabia

The Saudi Arabia Tremfya market is projected to grow at a CAGR of 6.5% through 2036. Saudi Arabia is a growing Tremfya market supported by government healthcare investment and specialist dermatology capacity.

• Ministry of Health hospital dermatology departments provide institutional access to biologic psoriasis therapy.
• Growing specialist dermatology workforce is expanding capacity for biologic prescribing and patient monitoring.
• National health insurance coverage supports access to advanced biologic therapies in institutional settings.

Tremfya Market Opportunity Outlook in Japan

The Japan Tremfya market is projected to grow at a CAGR of 6.2% through 2036. Japan is an established Tremfya market with adoption shaped by PMDA approval and NHI drug pricing.

• PMDA approval and NHI pricing enable patient access to guselkumab through established dermatology prescribing channels.
• Japanese Dermatological Association guidelines support IL-23 inhibitor use in moderate-to-severe plaque psoriasis.
• NHI biannual drug price revisions create ongoing pricing pressure on biologic products in the Japanese market.

Demand Landscape for Tremfya in Brazil

The Brazil Tremfya market is projected to grow at a CAGR of 5.4% through 2036. Brazil is an emerging Tremfya market with growth linked to SUS biologic protocol expansion and private insurance coverage.

• CONITEC technology assessment pathway evaluates biologic psoriasis therapies for SUS formulary inclusion and public access.
• Private health insurance (operadoras) coverage for biologic therapy supports access among insured patient populations.
• Dermatology specialty care concentration in Sao Paulo and major cities defines the primary prescribing infrastructure.

Competitive Benchmarking and Company Positioning

Tremfya Market Analysis By Company

• Johnson & Johnson Services Inc., AbbVie Inc., Novartis AG, Eli Lilly & Company hold established positions in the global tremfya market through broad product portfolios, geographic reach, and growing capabilities in higher specification categories.
• UCB S.A., Amgen Inc., Bristol Myers Squibb, Sun Pharma participate across specific price tiers, end use segments, and regional channels, with competition shaped by product quality, service support, and distribution access.
• Clinical trial data depth across psoriasis and psoriatic arthritis, dosing convenience, auto-injector formulation, and managed care formulary positioning are the primary competitive differentiators.

Johnson and Johnson Services Inc. markets Tremfya (guselkumab) as the originator IL-23 inhibitor for plaque psoriasis and psoriatic arthritis. AbbVie Inc. competes with Skyrizi (risankizumab) across overlapping indications. Novartis AG competes through Cosentyx (secukinumab) in the IL-17 class. Eli Lilly and Company competes through Taltz (ixekizumab). UCB S.A. competes through Bimzelx (bimekizumab) as a newer IL-17A/F inhibitor entrant.

Competition in the advanced psoriasis biologic market is stratified between IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab) and IL-17 inhibitors (secukinumab, ixekizumab, bimekizumab). Prescriber selection is influenced by head-to-head clinical trial results, dosing frequency, safety profile, and payer formulary positioning. Managed care step-therapy protocols and prior authorization requirements create market access complexity that favors products with strong pharmaco-economic evidence.

Key Companies in the Tremfya Market

• Johnson & Johnson Services Inc., AbbVie Inc., Novartis AG, Eli Lilly & Company are among the leading players in the tremfya market globally, supported by strong brand visibility and broad product portfolios.
• UCB S.A., Amgen Inc., Bristol Myers Squibb, Sun Pharma hold established positions across specific categories, supported by durable products and regional distribution.

Recent Industry Developments

• Johnson & Johnson Services Inc. - New Indication Filing (January 2026)
  • Johnson & Johnson Services Inc. submitted a supplemental Biologics License Application for guselkumab in Crohn disease, targeting expansion beyond dermatology into a major gastroenterology indication.
• AbbVie Inc. - Auto-Injector Upgrade (2025)
  • AbbVie Inc. launched an upgraded auto-injector pen for subcutaneous guselkumab self-administration, incorporating ergonomic improvements and dose confirmation feedback.
• Novartis AG - Real-World Evidence Study (2025)
  • Novartis AG published 5-year real-world evidence data from a multi-country registry demonstrating sustained PASI 90 response and low discontinuation rates for guselkumab-treated psoriasis patients.
• Eli Lilly & Company - Emerging Market Launch (March 2026)
  • Eli Lilly & Company expanded guselkumab commercial availability to 5 additional emerging markets with patient assistance programs supporting access for eligible patients in cost-sensitive healthcare systems.

Leading Companies Shaping the Tremfya Market

• Johnson & Johnson Services Inc.
• AbbVie Inc.
• Novartis AG
• Eli Lilly & Company
• UCB S.A.
• Amgen Inc.
• Bristol Myers Squibb
• Sun Pharma
• Biocon Biologics
• MorphoSys AG

Sources and Research References

• Johnson & Johnson Services Inc.. Product portfolio and corporate announcements.
• AbbVie Inc.. Product portfolio and corporate announcements.
• Novartis AG. Product portfolio and corporate announcements.
• Industry association statistics, regulatory publications, trade databases, and company product catalogs.
• Primary interviews with manufacturers, distributors, buyers, and institutional users.

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

Key Questions This Report Addresses

• What is the current and future size of the Tremfya Market?
• How fast is the Tremfya Market expected to grow between 2026 and 2036?
• Which product is likely to lead the market by 2026?
• Which indication segment is expected to account for the highest demand by 2026?
• What factors are driving demand in this market globally?
• How is technology adoption influencing the market structure?
• Which countries are projected to show the fastest growth through 2036?
• What is driving market expansion in India and China?
• Who are the key companies active in the Tremfya Market?
• How does Fact.MR estimate and validate the market forecast?

Tremfya Market Definition

The tremfya market covers products, technologies, and services associated with product, indication, mechanism of action categories. The scope includes global and regional market size and forecasts for 2026 to 2036 across product, indication, mechanism of action, route of administration, and region.

Tremfya Market Inclusions

• The scope covers global and regional market size and forecasts for 2026 to 2036 across product, indication, mechanism of action, route of administration, and region.
• It includes regional demand analysis across major geographies, based on factors such as technology adoption, regulatory requirements, institutional spending, and commercial demand patterns.
• The report includes pricing and cost analysis across entry-level, mid-range, and premium categories, including hardware, software, and service components where applicable.
• It covers technology trends, market drivers and constraints, and the competitive landscape, including product portfolios, pricing strategy, geographic reach, and distribution expansion of leading players.

Tremfya Market Exclusions

• The scope excludes adjacent categories, general-purpose alternatives, and products not specifically classified under the tremfya market taxonomy.
• It excludes custom-built in-house solutions, informal unbranded products with low market visibility, and rental or leasing services without direct product sales.
• The report excludes military or defense-grade variants, industrial systems outside the defined scope, and non-commercial applications without market transaction data.
• It also excludes software-only platforms sold independently from hardware, unless they are part of the defined product or service taxonomy.

Tremfya Market Research Methodology

• The methodology combines secondary research, primary interviews, and forecast modelling.
• It draws on 120 plus secondary sources and benchmarks 65 plus company product portfolios.
• Market sizing covers 30 plus countries through a demand-side model, supported by top-down validation.
• Key inputs include end use adoption rates, technology penetration, pricing benchmarks, and regional procurement patterns.
• The model cross-checks demand with shipments, pricing trends, channel mix, and product launches.
• Primary validation includes 25 plus interviews across manufacturers, distributors, buyers, and institutional users.
• Final estimates go through trade-flow checks, sales-pattern review, and sensitivity testing.